These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9797805)

  • 21. Neoadjuvant induction chemotherapy.
    Schwartz G
    Minerva Ginecol; 2005 Jun; 57(3):327-48. PubMed ID: 16166939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
    Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M
    Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy in breast cancer.
    Charfare H; Limongelli S; Purushotham AD
    Br J Surg; 2005 Jan; 92(1):14-23. PubMed ID: 15635596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
    Moore HC; Green SJ; Gralow JR; Bearman SI; Lew D; Barlow WE; Hudis C; Wolff AC; Ingle JN; Chew HK; Elias AD; Livingston RB; Martino S;
    J Clin Oncol; 2007 May; 25(13):1677-82. PubMed ID: 17404368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
    Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
    J Clin Oncol; 2004 Dec; 22(23):4691-9. PubMed ID: 15570071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
    Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
    Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Timing of radiotherapy in the treatment of breast carcinoma. Review of the literature].
    Trovò MG; Gigante M; Roncadin M; Arcicasa M; Bortolus R
    Ann Ital Chir; 1999; 70(3):371-6. PubMed ID: 10466240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: a multicenter evaluation.
    Vij R; DiPersio J; Brown R; Trinkaus K; Abboud C; Meehan KR; Frenette G; Freytes C; Goodnough LT; Khoury H; Ponnuri J; Adkins D
    Bone Marrow Transplant; 2000 Nov; 26(9):947-53. PubMed ID: 11100273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of neoadjuvant CMF to avoid mastectomy.
    George ML; Hale PC; Gumpert JR; Hogbin BM; Deutsch GP; Yelland A
    Eur J Surg Oncol; 1999 Feb; 25(1):50-3. PubMed ID: 10188855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
    Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
    Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
    Cottu PH; Extra JM; Espie M; Marolleau JP; de Roquancourt A; Makke J; Miclea JM; Laurence V; Mayeur D; Lerebours F; Cuvier C; Marty M
    Br J Cancer; 2001 Nov; 85(9):1240-6. PubMed ID: 11720455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of neoadjuvant chemotherapy for breast cancer treatment].
    Inaji H; Komoike Y; Motomura K; Kasugai T; Koyama H
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1113-9. PubMed ID: 12145989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
    Schwartz GF; Meltzer AJ; Lucarelli EA; Cantor JP; Curcillo PG
    J Am Coll Surg; 2005 Sep; 201(3):327-34. PubMed ID: 16125064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Breast cancer].
    Nomura Y
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):965-70. PubMed ID: 2730037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.